DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: BMS-914392
Drug: Placebo

First Posted Date: 2011-05-20

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT01356914

Locations: 🇬🇧
Eastbourne General Hospital, Eastbourne, United Kingdom

Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients

Completed

Conditions: Hepatitis B, Chronic

First Posted Date: 2011-05-20

Last Posted Date: 2015-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 230

Registration Number: NCT01356901

Locations: 🇩🇪
Local Institution, Herne, Germany

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Biological: nivolumab

First Posted Date: 2011-05-16

Last Posted Date: 2022-05-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 168

Registration Number: NCT01354431

Locations: 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸
North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States

and more 36 locations

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

Phase 1

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: Apixaban

First Posted Date: 2011-04-22

Last Posted Date: 2016-10-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01340586

A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials

Completed

Conditions: Hepatitis B

First Posted Date: 2011-04-19

Last Posted Date: 2011-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1097

Registration Number: NCT01337479

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

Phase 3

Completed

Conditions: HIV

Interventions: Drug: Atazanavir Sulphate
Drug: Ritonavir

First Posted Date: 2011-04-14

Last Posted Date: 2018-11-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 160

Registration Number: NCT01335698

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇬🇧
Local Institution, Birmingham, WEST Midlands, United Kingdom
🇺🇸
Children'S National Medical Center, Washington, District of Columbia, United States

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Biological: Elotuzumab (BMS-901608; HuLuc63)

First Posted Date: 2011-04-14

Last Posted Date: 2022-09-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 748

Registration Number: NCT01335399

Locations: 🇮🇱
Local Institution - 4959, Kfar Saba, Israel
🇷🇴
Local Institution - 5352, Bucuresti, Romania
🇵🇱
Local Institution - 5254, Gdansk, Poland

and more 232 locations

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Phase 4

Completed

Conditions: HIV, Combination Therapy

Interventions: Drug: Atazanavir
Drug: Ritonavir (heat-stable)
Drug: Tenofovir/Emtricitabine
Drug: Raltegravir

First Posted Date: 2011-04-11

Last Posted Date: 2015-02-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 132

Registration Number: NCT01332227

Locations: 🇺🇸
Health For Life Clinic Pllc, Little Rock, Arkansas, United States
🇺🇸
Eisenhower Medical Center, Palm Springs, California, United States
🇺🇸
Consultive Medicine, Daytona Beach, Florida, United States

and more 6 locations

Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 2

Completed

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: BMS-954561
Drug: Pregabalin
Drug: Placebo matching Pregabalin
Drug: Placebo matching BMS-954561

First Posted Date: 2011-03-14

Last Posted Date: 2015-12-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 178

Registration Number: NCT01314222

Locations: 🇺🇸
Comprehensive Clinical Development, Inc., St Petersburg, Florida, United States
🇫🇷
Local Institution, Nice Cedex 1, France
🇺🇸
Office Of Richard S. Cherlin, Md, Los Gatos, California, United States

and more 19 locations

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Biological: Pegylated Interferon Lambda (pegIFNλ)
Drug: BMS-790052 (NS5A Inhibitor)
Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a)
Drug: Ribavirin (RBV)
Drug: BMS-650032 (NS3 Protease Inhibitor)
Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)
Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)
Drug: Placebo for Ribavirin (RBV)

First Posted Date: 2011-03-07

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 165

Registration Number: NCT01309932

Locations: 🇺🇸
Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸
Desert Medical Group Inc., Palm Springs, California, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy